Takuji Murata

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

Shumpei Yokota, Tomoyuki Imagawa, Masaaki Mori et al. · The Lancet · 2008 · 797 citations

Medicine, Clinical Sciences, Pharmacotherapy +8

Dominant-negative STAT1 SH2 domain mutations in unrelated patients with mendelian susceptibility to mycobacterial disease

Miyuki Tsumura, Satoshi Okada, Hidemasa Sakai et al. · Human Mutation · 2012 · 84 citations · Full text

Life Sciences, Genetics, Microbiology +17

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan

Tomoyuki Imagawa, Syuji Takei, Hiroaki Umebayashi et al. · Clinical Rheumatology · 2012 · 77 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Longterm Safety and Effectiveness of the Anti-interleukin 6 Receptor Monoclonal Antibody Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan

Shumpei Yokota, Tomoyuki Imagawa, Masaaki Mori et al. · The Journal of Rheumatology · 2014 · 71 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis

Tomoyuki Imagawa, Shumpei Yokota, Masaaki Mori et al. · Modern Rheumatology · 2011 · 71 citations

Medicine, Immunology, Pediatrics +11